Skip to main content

Advertisement

Log in

Osteoporosis in men: recent progress

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

As osteoporosis in men has been recognized as an important clinical problem, new information is being accumulated on its scope, pathophysiology, evaluation, and treatment. Fracture risk calculators, such as FRAX, identify a large proportion of the older male population to be at heightened risk for fracture. The classification of osteoporosis into primary and secondary forms, while still useful, is affected by the fact that many men have multiple contributing factors to their fracture risk. The role of sex steroids is being better defined as other risk factors for fracture are delineated. As longevity continues to increase in men and until osteoporotic fracture is truly recognized as a potentially fatal disorder, many men will be undiagnosed and untreated. Two recent studies provide more evidence that treatments which decrease fracture risk in women do the same in men. With the publication of guidelines and increasing strength of evidence for treatment efficacy, it is hoped that more men will be evaluated and treated for this often neglected disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King, A.N. Toteston, Incidence and economic burden of osteoporosis-related fracture and subsequent fracture in men and women. JAMA 22, 365–475 (2007)

    Google Scholar 

  2. S. Khosla, L.J. Melton III, E.J. Atkinson, W.M. O’Falon, Relationship of serum sex steroids to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86, 3555–3561 (2001)

    Article  PubMed  CAS  Google Scholar 

  3. T.P. van Staa, E.M. Dennison, H.G. Leufkens, C. Cooper, Epidemiology of fractures in England and Wales. Bone 29, 517–522 (2001)

    Article  PubMed  Google Scholar 

  4. R.B. Hopkins, E. Pullenayegum, R. Goeree, J.D. Adachi, A. Papaioannou, W.E. Leslie, J.E. Tarride, L. Thabane, Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos. Int. 23, 921–927 (2012)

    Article  PubMed  CAS  Google Scholar 

  5. A.C. Feldstein, G. Nichols, E. Orwoll, P.J. Elmer, D.H. Smith, M. Herson, M. Aickin, The near absence of osteoporosis treatment in older men with fractures. Osteoporos. Int. 16, 953–962 (2005)

    Article  PubMed  Google Scholar 

  6. J.R. Center, D. Bliuc, T.V. Nguyen, J.A. Eisman, Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 24, 387–394 (2007)

    Article  Google Scholar 

  7. J.E. Block, H. Stubbs, Hip fracture-associated mortality reconsidered. Calcif. Tissue Int. 61, 84 (1997)

    Article  PubMed  CAS  Google Scholar 

  8. T.P. van Staa, H.G. Leufkens, L. Abenhaim, B. Zhang, C. Cooper, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxf.) 39, 1383–1389 (2000)

    Article  Google Scholar 

  9. R.A. Adler, M.C. Hochberg, Glucocorticoid-induced osteoporosis in men. J. Endocrinol. Investig. 34, 481–484 (2011)

    CAS  Google Scholar 

  10. G.L. Lu-Yao, P.C. Albertsen, D.F. Moore, W. Shih, Y. Lin, R.S. DiPaola, S.L. Yao, Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300, 173–181 (2008)

    Article  PubMed  CAS  Google Scholar 

  11. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, J.S. Goodwin, Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154–164 (2005)

    Article  PubMed  CAS  Google Scholar 

  12. B.L. Riggs, L.J. Melton III, Involutional osteoporosis. N. Engl. J. Med. 314, 1676–1686 (1986)

    Article  PubMed  CAS  Google Scholar 

  13. R.A. Adler, Osteoporosis in men: insights for the clinician. Ther Adv Musculoskelet Dis 3, 191–200 (2011)

    Article  PubMed  CAS  Google Scholar 

  14. J.A. Kanis, H. Johansson, A. Oden, B. Dawson-Hughes, L.J. Melton III, E.V. McCloskey, The effects of a FRAX revision for the USA. Osteoporos. Int. 21, 35–40 (2010)

    Article  PubMed  CAS  Google Scholar 

  15. N.D. Nguyen, S.A. Frost, J.R. Center, J.A. Eisman, T.V. Nguyen, Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos. Int. 18, 1109–1117 (2008)

    Article  Google Scholar 

  16. C.S. Ryan, V.I. Petkov, R.A. Adler, Osteoporosis in men: the value of laboratory testing. Osteoporos. Int. 22, 1845–1853 (2011)

    Article  PubMed  CAS  Google Scholar 

  17. E. Romagnoli, R. Del Fiacco, S. Russo, S. Piemonte, F. Fidanza, F. Colapietro, D. Diacinti, C. Cipriani, S. Minisola, Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. J. Rheumatol. 38, 1671–1679 (2011)

    Article  PubMed  Google Scholar 

  18. L.E. Ryan, S.W. Ing, Idiopathic hypercalciuria and bone health. Curr. Osteoporos. Rep. 10, 286–295 (2012)

    Article  PubMed  Google Scholar 

  19. P. Vestergaard, L. Rejnmark, L. Mosekilde, Fracture risk associated with the use of morphine and opiates. J. Intern. Med. 260, 76–87 (2006)

    Article  PubMed  CAS  Google Scholar 

  20. S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, M.R. Blackman, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86, 724–731 (2001)

    Article  PubMed  CAS  Google Scholar 

  21. J.M. Kaufman, A. Vermeulen, The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26, 833–876 (2005)

    Article  PubMed  CAS  Google Scholar 

  22. G. Sartorius, S. Spasevska, A. Idan, L. Turner, E. Forbes, A. Zamojska, C.A. Allan, L.P. Ly, A.J. Conway, R.I. McLachlan, D.J. Handelsman, Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin. Endocrinol. 77, 755–763 (2012)

    Article  CAS  Google Scholar 

  23. P. Dandona, S. Dhindsa, Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J. Clin. Endocrinol. Metab. 96, 2643–2651 (2011)

    Article  PubMed  CAS  Google Scholar 

  24. K.M. Wiren, A. Chapman Evans, X.W. Zhang, Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J. Endocrinol. 175, 683–694 (2002)

    Article  PubMed  CAS  Google Scholar 

  25. H. Lee, J.S. Finkelstein, M. Miller, S.J. Comeaux, R.I. Cohen, B.Z. Leder, Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J. Clin. Endocrinol. Metab. 91, 1069–1075 (2006)

    Article  PubMed  CAS  Google Scholar 

  26. D. Merlotti, L. Gennari, K. Stolakis, R. Nuti, Aromatase activity and bone loss in men. J. Osteoporos. 2011, 230671 (2011). doi:10.4061/2011/230671

    PubMed  Google Scholar 

  27. C.M. Nielson, L.M. Marshall, A.L. Adams, E.S. LeBlanc, P.M. Cawthon, K. Ensrud, E. Barrett-Connor, E.S. Orwoll, Osteoporotic Fractures in Men Study Research Group. BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J. Bone Miner. Res. 26, 496–502 (2011)

    Article  PubMed  Google Scholar 

  28. L.A. Fitzpatrick, Secondary causes of osteoporosis. Mayo Clin. Proc. 77, 453–468 (2002)

    PubMed  Google Scholar 

  29. R.A. Adler, Laboratory testing for secondary osteoporosis evaluation. Clin. Biochem. 45, 894–900 (2012)

    Article  PubMed  CAS  Google Scholar 

  30. G. Mazziotti, T. Porcelli, M. Mormando, E. De Menis, A. Bianchi, C. Mejia, T. Mancini, L. De Marinis, A. Giiustina, Vertebral fractures in males with prolactinoma. Endocrine 39, 288–293 (2011)

    Article  PubMed  CAS  Google Scholar 

  31. C. Torti, G. Mazziotti, P.A. Soldini, E. Foca, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)

    Article  PubMed  CAS  Google Scholar 

  32. T.T. Dam, S. Harrison, H.A. Fink, J. Ramsdell, E. Barrett-Connor, Osteoporotic Fractures in Men (MrOS) Research Group, Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos. Int. 21, 1341–1349 (2010)

    Article  PubMed  Google Scholar 

  33. G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)

    Article  PubMed  CAS  Google Scholar 

  34. C.E. Lewis, S.K. Ewing, B.C. Taylor, J.M. Shikany, H.A. Fink, K.E. Ensrud, E. Barrett-Connor, S.R. Cummings, E.S. Orwoll, Osteoporotic Fractures in Men (MrOs) Study Research Group, Predictors of non-spine fracture in elderly men: the MrOS Study. J. Bone Miner. Res. 22, 211–219 (2007)

    Article  PubMed  Google Scholar 

  35. J.A. Cauley, G. El Hajj Fuleihan, A. Arabi, S. Fujiwara, S. Ragi-Eis, A. Calderon, S.B. Chionh, Z. Chen, J.R. Curtis, M.E. Danielson, D.A. Hanley, H. Kroger, A.W. Kung, O. Lesnyak, J. Nieves, W. Pluskiewicz, R. El Rassi, S. Silverman, A.M. Schott, R. Rizzoli, M. Luckey, FRAX Position Conference Members, Official positions for FRAX clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis on FRAX. J. Clin. Densitom. 14, 240–262 (2011)

    Article  PubMed  Google Scholar 

  36. J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism. Arq. Bras. Endocrinol. Metab. 54, 106–109 (2010)

    Article  Google Scholar 

  37. N. Binkley, R.A. Adler, Dual-energy X-ray absorptiometry (DXA) in men, in Osteoporosis in Men, 2nd edn., ed. by E.S. Orwoll, J.P. Bilezikian, D. Vanderschueren (Academic Press, New York, 2010), pp. 525–540

    Chapter  Google Scholar 

  38. T. Isaksen, C.S. Nielsen, S.E. Christensen, P.H. Nissen, L. Heickendorff, L. Mosekilde, Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. Calcif. Tissue Int. 89, 285–294 (2011)

    Article  PubMed  CAS  Google Scholar 

  39. D.K. Dhanwal, N. Kochupillai, N. Gupta, C. Cooper, E.M. Dennison, Hypovitaminosis D and bone mineral metabolism and bone density in hyperthyroidism. J. Clin. Densitom. 13, 462–466 (2010)

    Article  PubMed  Google Scholar 

  40. D. Mittan, S. Lee, E. Miller, R.C. Perez, J.W. Basler, J.M. Bruder, Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 87, 3656–3661 (2002)

    Article  PubMed  CAS  Google Scholar 

  41. J.A. Kanis, L.J. Melton III, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone Miner. Res. 9, 1137–1141 (1994)

    Article  PubMed  CAS  Google Scholar 

  42. J.A. Kanis, G. Bianchi, J.P. Bilezikian, J.M. Kaufman, S. Khosla, E. Orwoll, E. Seeman, Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22, 2789–2798 (2011)

    Article  PubMed  CAS  Google Scholar 

  43. P.L. Selby, P.L. Davies, J.E. Adams, Do men and women fracture bones at similar bone densities? Osteoporos. Int. 11, 153–157 (2000)

    Article  PubMed  CAS  Google Scholar 

  44. R.A. Adler, Osteoporosis in men: what has changed? Curr. Osteoporos. Rep. 9, 31–35 (2011)

    Article  PubMed  Google Scholar 

  45. M.G. Donaldson, P.M. Cawthon, L.Y. Lui, J.T. Schousboe, K.E. Ensrud, B.C. Taylor, J.A. Cauley, T.A. Hillier, T.T. Dam, J.R. Curtis, D.M. Black, D.C. Bauer, E.S. Orwoll, S.R. Cummings, Osteoporotic Fractures in Men (MrOS) Study Group, Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation Guidelines. J. Bone Miner. Res. 25, 1506–1511 (2010)

    Article  PubMed  Google Scholar 

  46. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatment for osteoporosis. Endocrine 41, 58–69 (2012)

    Article  PubMed  CAS  Google Scholar 

  47. E.S. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343, 604–610 (2000)

    Article  PubMed  CAS  Google Scholar 

  48. L.H. Klotz, I.Y. McNeill, M. Kebabdjian, L. Zhang, J. Chin, Canadian Urology Research Consortium, A phase 3, double-blind, randomized, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study. Eur. Urol. doi:10.1016/j.eururu.2012.09.007

  49. S. Boonen, E.S. Orwoll, D. Wenderoth, K.J. Stoner, R. Eusebio, P.D. Delmas, Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 24, 719–725 (2009)

    Article  PubMed  CAS  Google Scholar 

  50. P. Taxel, R. Dowsett, L. Richter, P. Fall, A. Klepinger, P. Albertsen, Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int. 106, 1473–1476 (2010)

    Article  PubMed  CAS  Google Scholar 

  51. E.S. Orwoll, N.C. Binkley, E.M. Lewiecki, U. Gruntmanis, M.A. Fries, G. Dasic, Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46, 970–976 (2010)

    Article  PubMed  CAS  Google Scholar 

  52. E.S. Orwoll, P.D. Miller, J.D. Adachi, J. Brown, R.A. Adler, D. Kendler, C. Bucci-Rechtweg, A. Readie, P. Messenbrink, R.S. Weinstein, Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res. 25, 2239–2250 (2010)

    Article  PubMed  CAS  Google Scholar 

  53. S. Boonen, J.Y. Reginster, J.M. Kaufman, K. Lippuner, J. Zanchetta, B. Langdahl, R. Rizzoli, S. Lipschitz, H.P. Dimai, R. Witvrouw, E. Eriksen, K. Brixen, L. Russo, F. Claessens, P. Papanastasiou, O. Antunez, G. Su, C. Bucci-Rechtweg, J. Hruska, E. Incera, D. Vanderschueren, E. Orwoll, Fracture risk and zoledronic acid therapy in men with osteoporosis. N. Engl. J. Med. 367, 1714–1723 (2012)

    Article  PubMed  CAS  Google Scholar 

  54. K. Sinningen, E. Tsourdi, M. Rauner, T.D. Rachner, C. Hamann, L.C. Hofbauer, Skeletal and extraskeletal actions of denosumab. Endocrine 42, 52–62 (2012)

    Article  PubMed  CAS  Google Scholar 

  55. E. Orwoll, C.S. Teglbjaerg, B.L. Langdahl, R. Chapurlat, E. Czerwinski, D.L. Kendler, J.Y. Reginster, A. Kivitz, E.M. Lewiecki, P.D. Miller, M.A. Bolognese, M.R. McClung, H.G. Bone, P. Ljimggrem, B. Abrahamsne, U. Gruntmanis, Y.C. Yang, R.B. Wagman, S. Siddhanti, A. Grauer, J.W. Hall, S. Boonen, A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J. Clin. Endocrinol. Metab. 97, 3161–3169 (2012)

    Article  PubMed  CAS  Google Scholar 

  56. M.R. Smith, B. Egerdie, N.H. Toriz, R. Feldman, T.L. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, B.Z. Leder, C. Goessl, Denosumab HALT Prostate Cancer Study Group, Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009)

    Article  PubMed  CAS  Google Scholar 

  57. N.E. Cusano, A.G. Costa, B.C. Silva, J.P. Bilezikian, Therapy of osteoporosis in men with teriparatide. J. Osteoporos. 2011, 463675 (2011). doi:10.4061/2011/463675

  58. J.M. Kaufman, E. Orwoll, S. Goemaere, J. San Martin, A. Hossain, G.P. Dalsky, R. Linsday, B.H. Mitlak, Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 16, 510–516 (2005)

    Article  PubMed  CAS  Google Scholar 

  59. J.D. Ringe, A. Dorst, P. Farahmand, Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung 60, 267–272 (2010)

    PubMed  CAS  Google Scholar 

  60. H.M. Behre, S. Kliesch, E. Leifke, T.M. Link, E. Nieschlag, Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 82, 2386–2390 (1997)

    Google Scholar 

  61. J.K. Amory, N.B. Watts, K.A. Easley, P.R. Sutton, B.D. Anawalt, A.M. Matsumoto, W.J. Bremer, J.L. Tenover, Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89, 503–510 (2004)

    Article  PubMed  CAS  Google Scholar 

  62. P.J. Snyder, H. Peachey, P. Hannoush, J.A. Berlin, L. Loh, J.H. Holmes, A. Dlewati, J. Staley, J. Santanna, S.C. Kapoor, M.F. Attie, J.G. Haddad Jr., B.L. Strom, Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84, 1966–1972 (1999)

    Article  PubMed  CAS  Google Scholar 

  63. N.B. Watts, R.A. Adler, J.P. Bilezikian, M.T. Drake, R. Eastell, E.S. Orwoll, J.S. Finkelstein, Osteoporosis in men: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 97, 1802–1822 (2012)

    Article  PubMed  CAS  Google Scholar 

  64. J. Compston, Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos. Int. 22, 2951–2961 (2011)

    Article  PubMed  CAS  Google Scholar 

  65. S.V. Reddy, S.K. Gupta, Atypical femoral shaft fractures in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singap. Med. J. 53, e52–e54 (2012)

    CAS  Google Scholar 

  66. N.B. Watts, D.L. Diab, Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 95, 1555–1565 (2010)

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert A. Adler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adler, R.A. Osteoporosis in men: recent progress. Endocrine 44, 40–46 (2013). https://doi.org/10.1007/s12020-013-9880-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-9880-7

Keywords

Navigation